To contentTo navigationTo search
Logotype

News & Events

Press Releases


2024

Implantica submits U.S. FDA Premarket Approval (PMA) application for RefluxStop® (first module)

27.03.2024
 | Other press releases
Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, announces the submission of the first module of the PMA application to the U.S. FDA for RefluxStop®, an innovative device for the treatment of Gastroesophageal Reflux Disease (GERD).

Implantica completes Human Factors Validation Study for RefluxStop™ as part of the US FDA Premarket Approval Process

26.03.2024
 | Other press releases
Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, announces completion of the Human Factors Validation Study with 16 US surgeons as part of the US FDA Premarket Approval (PMA) process for RefluxStop™.

Implantica wins another RefluxStop™ public tender in Europe, this time in Spain with Hospital Universitario de Getafe

19.03.2024
 | Other press releases
Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, announces the first-in-the-country public tender win for RefluxStop™ at Hospital Universitario de Getafe, a public hospital in Madrid, Spain.

Implantica announces another major public hospital purchase agreement win in Italy, further strengthening RefluxStop™’s broader acceptance in public healthcare systems in Europe

05.03.2024
 | Other press releases
Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, announces another public hospital purchase agreement for RefluxStop™ this time at the IRCCS Saverio De Bellis in Bari, Puglia, Italy.

Implantica publishes Year-end Report, January – December 2023 (Q4)

16.02.2024
 | Regulatory
RefluxStop™ – Gaining speed, breaking boundaries and going global

Implantica’s RefluxStop™ now available in Munich

15.02.2024
 | Other press releases
Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, announces the first RefluxStop™ procedures completed at Artemed Klinikum München Süd in Munich, Germany.

Implantica announces first RefluxStop™ public tender win, paving the way for permanent reimbursement in Italy

13.02.2024
 | Other press releases
Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, announces that Hospital Santa Croce of Moncalieri, Turin, Regione Piemonte, Italy, has won the first-ever public tender for RefluxStop™.

Implantica continues to expand in Germany with another reflux Center of Excellence in Berlin

06.02.2024
 | Other press releases
Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, announces the first RefluxStop[TM] procedures completed at MIC Hospital in Berlin.

Implantica presents the fourth quarter 2023 on February 16 at 15:00 CET

05.02.2024
 | Other press releases
Implantica AG (publ) invites investors to a presentation of the fourth quarter 2023 at 15:00 CET on February 16. The interim report for the fourth quarter will be published at 8:00 a.m. CET on the same day.

Implantica's RefluxStop™ featured in seven presentations accepted at the largest US GI conference, SAGES

01.02.2024
 | Other press releases
Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, reports that seven new scientific data presentations and abstracts on RefluxStop™ have been accepted at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Annual Scientific Meeting in Cleveland, Ohio, April 17-20, 2024.
Load more